Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – IT Business Net
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine…
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2,…
-
General7 hours agoRSL NSW president Mick Bainbridge and three board members resign in wake of 7.30 investigation into conflicts of interest
-
General18 hours agoNewsCorp executive warns AI firms are asking Australia to ‘surrender our stories’
-
General13 hours agoRenters surprise winners from cheaper mortgage deposits
-
General10 hours agoSelf-taught child drummer makes rock band debut with The Living End